GSTP1与ERCC1基因多态性与局部晚期头颈癌铂类放化疗毒性的关联
研究纳入110例接受顺铂为基础放化疗的局部晚期头颈鳞癌患者,对29个基因的36个单核苷酸多态性(SNP)进行基因分型,分析其与急性毒性的关联。结果发现ERCC1 rs11615-C、rs735482-C及ERCC4 rs1799801-C等位基因与较低2-3级血液学毒性风险相关,GSTP1 G等位基因与严重吞咽困难风险显著降低相关。作者认为ERCC1和GSTP1多态性可能作为放化疗急性毒性的预后因素。
要点
- ERCC1 rs11615-C、rs735482-C及ERCC4 rs1799801-C与较低2-3级血液学毒性风险相关。
- GSTP1 G等位基因与严重吞咽困难风险显著降低相关(P = .0004)。
- 作者认为ERCC1和GSTP1多态性可能作为放化疗急性毒性的预后因素。
核心结论
- ERCC1和GSTP1基因多态性可能作为头颈鳞癌患者放化疗期间急性毒性的预后因素。
研究设计与样本
- 在110例接受顺铂为基础放化疗的局部晚期头颈鳞癌患者中,对29个基因的36个选定单核苷酸多态性(SNP)进行基因分型,DNA取自血样,采用MassARRAY iPLEX Gold(Sequenom)法分析。
主要发现
- 携带ERCC1 rs11615-C等位基因的患者2-3级血液学毒性风险较低(P = .0066)。
- 携带ERCC1 rs735482-C等位基因的患者2-3级血液学毒性风险较低(P = .0204)。
- 携带ERCC4 rs1799801-C等位基因的患者2-3级血液学毒性风险较低(P = .0286)。
- 携带GSTP1 G等位基因与严重吞咽困难风险显著降低相关(P = .0004)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-based chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck squamous-cell carcinomas (HNSCC), and most patients experience serious toxicities. The aim of this study was to investigate the association between candidate genes involved in radiation/platinum pathways and acute toxicity of CRT to determine the predictive value of these polymorphisms for toxicity. METHODS: Thirty-six selected single nucleotide polymorphisms (SNPs) in 29 genes were genotyped in 110 patients treated with cisplatin-based CRT. DNA was obtained from blood samples, and SNP analysis was performed using a MassARRAY iPLEX Gold (Sequenom) method. RESULTS: Patients with ERCC1 rs11615-C allele (P = .0066), ERCC1 rs735482-C allele (P = .0204), and ERCC4 rs1799801-C allele (P = .0286) had lower risk of grade 2-3 hematologic toxicity. In addition, the presence of G allele of GSTP1 was associated with a significantly lower risk of severe dysphagia (P = .0004). CONCLUSION: Polymorphisms in ERCC1 and GSTP1 may act as prognostic factors of acute toxicity during treatment with CRT in HNSCC patients.
引用
- Duran G, Aguín S, Cruz R, et al. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment. Head Neck. 2019. PMID: 30973677. doi:10.1002/hed.25754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。